Lack of association between nuclear factor erythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  LoGerfo, Annalisa ^a   Chico, Lucia ^a   Borgia, Loredana ^a   Petrozzi, Lucia ^a   Rocchi, Anna ^a   D'Amelio, Antonia ^a   Carlesi, Cecilia ^a   Caldarazzo Ienco, Elena ^a   Mancuso, Michelangelo ^a   Siciliano, Gabriele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENES; NEURODEGENERATIVE DISEASES; NEURONS;

ADVANCED OXIDATION; AMYOTROPHIC LATERAL SCLEROSIS; BIOCHEMICAL MARKERS; CELLULAR FUNCTION; COMPLEX MECHANISMS; GENE POLYMORPHISM; OXIDATIVE STRESS BIOMARKERS; PATHOGENIC MECHANISMS;

OXIDATIVE STRESS;

ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; GENOMIC DNA; GLUTATHIONE; IMMUNOGLOBULIN; IRON REDUCING ABILITY OF PLASMA PROTEIN; PLASMA PROTEIN; THIOL; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NFE2L2 PROTEIN, HUMAN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INCUBATION TIME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; PROMOTER REGION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

ADVANCED OXIDATION PROTEIN PRODUCTS; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84896135587     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/432626     Document Type: Article

References (57)

1. Miana-Mena F. J., González-Mingot C., Larrodé P., Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis. Journal of Neurological Disorders 2010 258 5 762 769
2. Maimone D., Dominici R., Grimaldi L. M. E., Pharmacogenomics of neurodegenerative diseases. European Journal of Pharmacology 2001 413 1 11 29 2-s2.0-0035830630 10.1016/S0014-2999(00)00939-0 (Pubitemid 32150054)
3. Mancuso M., Coppede F., Migliore L., Siciliano G., Murri L., Mitochondrial dysfunction, oxidative stress and neurodegeneration. Journal of Alzheimer's Disease 2006 10 1 59 73 2-s2.0-33748757300 (Pubitemid 44401367)
4. Barber S. C., Higginbottom A., Mead R. J., Barber S., Shaw P. J., An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radical Biology and Medicine 2009 46 8 1127 1138 2-s2.0-63049135666 10.1016/j.freeradbiomed.2009.01.019
5. Bergström P., Andersson H. C., Gao Y., Karlsson J.-O., Nodin C., Anderson M. F., Nilsson M., Hammarsten O., Repeated transient sulforaphane stimulation in astrocytes leads to prolonged Nrf2-mediated gene expression and protection from superoxide-induced damage. Neuropharmacology 2011 60 2-3 343 353 2-s2.0-78650814146 10.1016/j.neuropharm.2010.09.023
6. Perry G., Nunomura A., Hirai K., Zhu X., Prez M., Avila J., Castellani R. J., Atwood C. S., Aliev G., Sayre L. M., Takeda A., Smith M. A., Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radical Biology and Medicine 2002 33 11 1475 1479 2-s2.0-18744374615 10.1016/S0891-5849(02)01113-9 (Pubitemid 35351590)
7. Carlesi C., Pasquali L., Piazza S., Lo Gerfo A., Caldarazzo Ienco E., Alessi R., Fornai F., Siciliano G., Strategies for clinical approach to neurodegeneration in amyotrophic lateral sclerosis. Archives Italiennes de Biologie 2011 149 1 151 167 2-s2.0-79952848269
8. Nassif M., Matus S., Castillo K., Hetz C., Amyotrophic lateral sclerosis pathogenesis: a journey through the secretory pathway. Antioxidants and Redox Signaling 2010 13 12 1955 1989 2-s2.0-78149339310 10.1089/ars.2009.2991
9. von Otter M., Landgren S., Nilsson S., Celojevic D., Bergström P., Håkansson A., Nissbrandt H., Drozdzik M., Bialecka M., Kurzawski M., Blennow K., Nilsson M., Hammarsten O., Zetterberg H., Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Medical Genetics 2010 11 1, article 36 2-s2.0-77951176535 10.1186/1471-2350-11-36
10. Johnson J. A., Johnson D. A., Kraft A. D., Calkins M. J., Jakel R. J., Vargas M. R., Chen P.-C., The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Annals of the New York Academy of Sciences 2008 1147 61 69 2-s2.0-57649213538 10.1196/annals.1427.036
11. Holmström K. M., Baird L., Zhang Y., Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biology Open 2013 2 8 761 770
12. Vargas M. R., Pehar M., Cassina P., Martínez-Palma L., Thompson J. A., Beckman J. S., Barbeito L., Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. Journal of Biological Chemistry 2005 280 27 25571 25579 2-s2.0-21844474290 10.1074/jbc.M501920200 (Pubitemid 40962264)
13. Mimoto T., Miyazaki K., Morimoto N., Kurata T., Satoh K., Ikeda Y., Abe K., Impaired antioxydative Keap1/Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice. Brain Research 2012 1446 109 118 2-s2.0-84858451400 10.1016/j.brainres.2011.12.064
14. Sarlette A., Krampfl K., Grothe C., Neuhoff N. V., Dengler R., Petri S., Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology 2008 67 11 1055 1062 2-s2.0-58149232639 10.1097/NEN.0b013e31818b4906
15. Pehar M., Vargas M. R., Robinson K. M., Cassina P., Díaz-Amarilla P. J., Hagen T. M., Radi R., Barbeito L., Beckman J. S., Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. Journal of Neuroscience 2007 27 29 7777 7785 2-s2.0-34447633192 10.1523/JNEUROSCI.0823-07. 2007 (Pubitemid 47093805)
16. Vargas M. R., Johnson D. A., Sirkis D. W., Messing A., Johnson J. A., Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. Journal of Neuroscience 2008 28 50 13574 13581 2-s2.0-58149379610 10.1523/JNEUROSCI.4099-08.2008
17. Kraft A. D., Resch J. M., Johnson D. A., Johnson J. A., Activation of the Nrf2-ARE pathway in muscle and spinal cord during ALS-like pathology in mice expressing mutant SOD1. Experimental Neurology 2007 207 1 107 117 2-s2.0-34548287969 10.1016/j.expneurol.2007.05.026 (Pubitemid 47332487)
18. Cho H. Y., Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2. Oxidative Medicine and Cellular Longevity 2013 2013 286524 10.1155/2013/286524
19. Robertson K. A., Hill D. P., Kelley M. R., Tritt R., Crum B., Van Epps S., Srour E., Rice S., Hromas R., The myeloid zinc finger gene (MZF-1) delays retinoic acid-induced apoptosis and differentiation in myeloid leukemia cells. Leukemia 1998 12 5 690 698 2-s2.0-0031897345 (Pubitemid 28220821)
20. Reddy S. P. M., Mossman B. T., Role and regulation of activator protein-1 in toxicant-induced responses of the lung. The American Journal of Physiology 2002 283 6 L1161 L1178 2-s2.0-0036891937 (Pubitemid 35379247)
21. Itoh K., Tong K. I., Yamamoto M., Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radical Biology and Medicine 2004 36 10 1208 1213 2-s2.0-1942455887 10.1016/j.freeradbiomed.2004.02.075 (Pubitemid 38526314)
22. Ryu J., Zhang R., Hong B. H., Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing nrf2 activity. PLoS ONE 2013 8 8 e71178
23. von Otter M., Landgren S., Nilsson S., Zetterberg M., Celojevic D., Bergström P., Minthon L., Bogdanovic N., Andreasen N., Gustafson D. R., Skoog I., Wallin A., Tasa G., Blennow K., Nilsson M., Hammarsten O., Zetterberg H., Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mechanisms of Ageing and Development 2010 131 2 105 110 2-s2.0-77249083614 10.1016/j.mad.2009.12.007
24. Marzec J. M., Christie J. D., Reddy S. P., Jedlicka A. E., Vuong H., Lanken P. N., Aplenc R., Yamamoto T., Yamamoto M., Cho H.-Y., Kleeberger S. R., Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. The FASEB Journal 2007 21 9 2237 2246 2-s2.0-34347392512 10.1096/fj.06-7759com (Pubitemid 47026458)
25. Witko-Sarsat V., Friedlander M., Capeillère-Blandin C., Nguyen-Khoa T., Nguyen A. T., Zingraff J., Jungers P., Descamps-Latscha B., Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 1996 49 5 1304 1313 2-s2.0-0029948839 (Pubitemid 26166404)
26. Benzie I. F. F., Strain J. J., The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Analytical Biochemistry 1996 239 1 70 76 2-s2.0-0030586361 10.1006/abio.1996.0292 (Pubitemid 26256285)
27. Hu M.-L., Measurement of protein thiol groups and glutathione in plasma. Methods in Enzymology 1994 233 380 385 2-s2.0-0028283301 10.1016/S0076-6879(94) 33044-1
28. Matsumoto Y., Suzuki A., Ishii G., Oshino S., Otani K., Goto K., The -181 A/C polymorphism in the excitatory amino acid transporter-2 gene promoter affects the personality trait of reward dependence in healthy subjects. Neuroscience Letters 2007 427 2 99 102 2-s2.0-35448982655 10.1016/j.neulet.2007. 09.015 (Pubitemid 47633791)
29. Beal M. F., Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology 2005 58 4 495 505 2-s2.0-25444474703 10.1002/ana.20624 (Pubitemid 41377212)
30. Siciliano G., Piazza S., Carlesi C., Del Corona A., Franzini M., Pompella A., Malvaldi G., Mancuso M., Paolicchi A., Murri L., Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. Journal of Neurology 2007 254 5 575 580 2-s2.0-34249026030 10.1007/s00415-006- 0301-1 (Pubitemid 46781962)
31. Keizman D., Ish-Shalom M., Berliner S., Maimon N., Vered Y., Artamonov I., Tsehori J., Nefussy B., Drory V. E., Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? Journal of the Neurological Sciences 2009 285 1-2 95 99 2-s2.0-69549116245 10.1016/j.jns.2009. 06.002
32. Vogel C., Silva G. M., Marcotte E. M., Protein expression regulation under oxidative stress. Molecular & Cellular Proteomics 2011 10 12 M111.009217 2-s2.0-84859236011
33. Tanaka F., Ikenaka K., Yamamoto M., Sobue G., Neuropathology and omics in motor neuron diseases. Neuropathology 2012 32 4 458 462 2-s2.0-84055223065 10.1111/j.1440-1789.2011.01281.x
34. Rossi L., Valle C., Carrì M. T., Altered gene expression, mitochondrial damage and oxidative stress: converging routes in motor neuron degeneration. International Journal of Cell Biology 2012 2012 9 908724 10.1155/2012/908724
35. Bäumer D., Ansorge O., Almeida M., Talbot K., The role of RNA processing in the pathogenesis of motor neuron degeneration. Expert reviews in molecular medicine 2010 12, article e21 2-s2.0-77956996059 10.1017/ S1462399410001523
36. Smith H. S., The role of genomic oxidative-reductive balance as predictor of complex regional pain syndrome development: a novel theory. Pain Physician 2010 13 1 79 90 2-s2.0-76149100903
37. Petri S., Körner S., Kiaei M., Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurology Research International 2012 2012 7 878030 10.1155/2012/878030
38. Li W., Kong A.-N., Molecular mechanisms of Nrf2-mediated antioxidant response. Molecular Carcinogenesis 2009 48 2 91 104 2-s2.0-59849113546 10.1002/mc.20465
39. Motohashi H., Yamamoto M., Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends in Molecular Medicine 2004 10 11 549 557 2-s2.0-7244253081 10.1016/j.molmed.2004.09.003 (Pubitemid 39433824)
40. Frautschy S. A., Hu W., Kim P., Miller S. A., Chu T., Harris-White M. E., Cole G. M., Phenolic anti-inflammatory antioxidant reversal of A β -induced cognitive deficits and neuropathology. Neurobiology of Aging 2001 22 6 993 1005 2-s2.0-0035686083 10.1016/S0197-4580(01)00300-1 (Pubitemid 34070638)
41. Abdel-Wahab M. H., Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity: induced by 1-methyl-4-(2′- methylphenyl)-1,2,3,6-tetrahydropyridine (2′-methyl-MPTP) in mice. Journal of Biochemical and Molecular Toxicology 2005 19 1 32 41 2-s2.0-14644436461 10.1002/jbt.20053 (Pubitemid 40315389)
42. Kanninen K., Malm T. M., Jyrkkänen H.-K., Goldsteins G., Keksa-Goldsteine V., Tanila H., Yamamoto M., Ylä-Herttuala S., Levonen A.-L., Koistinaho J., Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Molecular and Cellular Neuroscience 2008 39 3 302 313 2-s2.0-53749088028 10.1016/j.mcn.2008.07.010
43. Chen P.-C., Vargas M. R., Pani A. K., Smeyne R. J., Johnson D. A., Kan Y. W., Johnson J. A., Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proceedings of the National Academy of Sciences of the United States of America 2009 106 8 2933 2938 2-s2.0-62449132771 10.1073/pnas.0813361106
44. Dumont M., Wille E., Calingasan N. Y., Tampellini D., Williams C., Gouras G. K., Liby K., Sporn M., Flint Beal M., Lin M. T., Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry 2009 109 2 502 512 2-s2.0-62649115489 10.1111/j.1471-4159.2009.05970.x
45. Kanninen K., Heikkinen R., Malm T., Rolova T., Kuhmonen S., Leinonen H., Ylä-Herttuala S., Tanila H., Levonen A.-L., Koistinaho M., Koistinaho J., Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2009 106 38 16505 16510 2-s2.0-70349482547 10.1073/pnas.0908397106
46. Yang L., Calingasan N. Y., Thomas B., Charturvedi R. K., Kiaei M., Wille E. J., Liby K. T., Williams C., Royce D., Risingson R., Musiek E. S., Morrow J. D., Sporn M., Beal M. F., Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE 2009 4 6 2-s2.0-66749132810 10.1371/journal.pone.0005757 e5757
47. Stack C., Ho D., Wille E., Calingasan N. Y., Williams C., Liby K., Sporn M., Dumont M., Beal M. F., Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology and Medicine 2010 49 2 147 158 2-s2.0-77953537441 10.1016/j.freeradbiomed.2010.03. 017
48. Hickey M. A., Zhu C., Medvedeva V., Lerner R. P., Patassini S., Franich N. R., Maiti P., Frautschy S. A., Zeitlin S., Levine M. S., Chesselet M.-F., Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Molecular Neurodegeneration 2012 7 12 1326 1327 2-s2.0-84859189953
49. Boettler U., Volz N., Teller N., Haupt L. M., Bakuradze T., Eisenbrand G., Bytof G., Lantz I., Griffiths L. R., Marko D., Induction of antioxidative Nrf2 gene transcription by coffee in humans: depending on genotype? Molecular Biology Reports 2012 39 6 7155 7162 2-s2.0-84856583639 10.1007/s11033-012-1547-6
50. Córdova E. J., Velázquez-Cruz R., Centeno F., Baca V., Orozco L., The NRF2 gene variant, -653G/A, is associated with nephritis in childhood-onset systemic lupus erythematosus. Lupus 2010 19 10 1237 1242 2-s2.0-77956252901 10.1177/0961203310367917
51. Satoh T., McKercher S. R., Lipton S. A., Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radical Biology and Medicine 2013 65 645 657
52. Ghosh D., Levault K. R., Brewer G. J., Dual-energy precursor and nuclear erythroid-related factor 2 activator treatment additively improve redox glutathione levels and neuron survival in aging and Alzheimer mouse neurons upstream of reactive oxygen species. Neurobiology of Aging 2014 35 1 179 190
53. Ghosh D., LeVault K. R., Barnett A. J., Brewer G. J., A reversible early oxidized redox state that precedes macromolecular ROS damage in aging nontransgenic and 3xTg-AD mouse neurons. Journal of Neuroscience 2012 32 17 5821 5832 2-s2.0-84860170321 10.1523/JNEUROSCI.6192-11.2012
54. Neymotin A., Calingasan N. Y., Wille E., Naseri N., Petri S., Damiano M., Liby K. T., Risingsong R., Sporn M., Beal M. F., Kiaei M., Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology and Medicine 2011 51 1 88 96 2-s2.0-79957959973 10.1016/j.freeradbiomed.2011.03.027
55. Guo Y., Zhang Y., Wen D., The modest impact of transcription factor Nrf2 on the course of disease in an ALS animal model. Laboratory Investigation 2013 93 7 825 833
56. Mead R. J., Higginbottom A., Allen S. P., S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radical Biology and Medicine 2013 61 438 452
57. Nanou A., Higginbottom A., Valori C. F., Wyles M., Ning K., Shaw P., Azzouz M., Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis. Molecular Therapy 2013 21 8 1486 1496